Gleevec
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Chronic-Phase
Conditions
Leukemia, Myeloid, Chronic-Phase
Trial Timeline
Mar 1, 2001 → Aug 1, 2013
NCT ID
NCT00048672About Gleevec
Gleevec is a phase 2 stage product being developed by Novartis for Leukemia, Myeloid, Chronic-Phase. The current trial status is completed. This product is registered under clinical trial identifier NCT00048672. Target conditions include Leukemia, Myeloid, Chronic-Phase.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00081926 | Approved | Completed |
| NCT00230334 | Phase 2 | Terminated |
| NCT00038649 | Phase 2 | Terminated |
| NCT00048672 | Phase 2 | Completed |
Competing Products
20 competing products in Leukemia, Myeloid, Chronic-Phase